Newsroom | 55884 results

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 182,800 common shares of the Company (the "Options") with effective grant dates of September 15, 2025 and September 22, 2025, depending...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 European Society for Medical Oncology...

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced two upcoming oral presentations highlighting the company’s lead-candidate visugromab at the European Society of Medical Oncology (ESMO) Congress, being held October 17th-21st, 2025, in Berlin, Germany. Visugromab is a humanized, monoclonal antibody designed to neutralize the tumor-derived cytokine Growth Differentiation Factor-15 (GDF-15) that plays a central role in i...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--Global Healthy Living Foundation and Medscape Education Announce Partnership...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp.™ (« MindWalk », « la Société » ou « nous ») (Nasdaq : HYFT), une société d'IA bio-native, a annoncé aujourd'hui une avancée majeure dans son programme thérapeutique GLP-1 conçu par IA. De nouvelles données issues de la plateforme LensAI™ de la Société révèlent un lien jusqu'alors méconnu entre la biologie du GLP-1 et une seconde voie, non chevauchante, essentielle au vieillissement en bonne santé et à la résilience systémique. Ces résultat...

WINNIPEG, Manitoba--(BUSINESS WIRE)--The Bioscience Association Manitoba (BAM) is excited to join communities around the world in celebrating Global Biotech Week, taking place September 21 – 27, 2025. This annual celebration highlights the transformative power of biotechnology and bioscience, showcasing breakthroughs, innovations, and the incredible contributions of Manitoba’s growing sector. To mark the occasion, BAM will host a special proclamation event at the Manitoba Legislative Building o...

MUNICH--(BUSINESS WIRE)--Tubulis today announced that its late-breaking abstract covering first clinical data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025, in Berlin. The presentation by the principal investigator of the study, Dr. Antonio Gonzalez-Martin, will provide interim data from the dose escalation part of the ovarian cancer cohor...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, today announced that Fierce Biotech has named it as one of 2025’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising private biotechnology companies in the industry. “Being named to the Fierce 15 is a recognition of the bold science our team is advancing to change the course of age-related eye disease...

OXFORD, England--(BUSINESS WIRE)--OGT, a leading global provider of genomic diagnostic and research solutions, announced today that the U.S. Food and Drug Administration (FDA) has granted their De Novo Classification Request for the CytoCell® KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s first-in-class menin inhibitor, REVUFORJ® (revumenib). Revuforj is FDA approved for the treatment of relapsed or refractory (R/R) acute leukaemia with a lysine methyltransfera...

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Announces $60 Million Series B Financing...